Tolerizing Nanoparticle Preparation for Peanut Protein Encapsulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune tolerizing therapies for peanut allergy, such as oral, subcutaneous, and sublingual immunotherapy, rely on chronic administration of free peanut proteins, posing a risk of adverse reactions like anaphylaxis due to immune activation, and have not achieved true tolerance.
Innovation Solution
The development of tolerizing immune modifying particles (TIMPs) encapsulating peanut proteins, optimized through a process involving emulsion formation, solvent removal, and freeze drying, to ensure safe and therapeutic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If free peanut proteins are administered chronically to induce tolerance, then immune tolerance may be achieved, but the risk of adverse reactions including anaphylaxis increases due to immune activation
Solution Approach 1:
The patent uses an emulsion system as an intermediary carrier to deliver peanut proteins. The emulsion consists of an aqueous phase containing peanut proteins and an oil phase containing a polymer, creating a controlled delivery system that prevents direct exposure of free peanut proteins to the immune system while still allowing antigen presentation for tolerance induction
Solution Approach 2:
The patent changes the physical state and delivery parameters of peanut proteins by encapsulating them in an emulsion system. This modifies how the proteins are presented to the immune system, controlling release kinetics and reducing erratic immune activation that leads to anaphylaxis
2Object-affected harmful factors
If encapsulation efficiency is increased to improve safety, then the risk of immune activation is reduced, but the manufacturing complexity increases
Solution Approach 1:
The manufacturing process is segmented into distinct steps: forming a primary emulsion with peanut proteins and polymer, then forming a secondary emulsion by adding surfactants and stabilizers. This segmentation allows optimization of each step independently to achieve high encapsulation efficiency while maintaining manageable manufacturing complexity
Solution Approach 2:
The patent employs specific parameter ranges for pH (2-8), temperature (4-25°C), and component ratios to optimize encapsulation efficiency. These controlled parameter changes ensure high encapsulation while keeping the manufacturing process through standardized, scalable procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process ensures efficient encapsulation of peanut proteins within nanoparticles, reducing the risk of immune activation and adverse reactions, promoting antigen-specific tolerance and potential cure for peanut allergy.
Implementation Method 1
generating a primary emulsion by mixing an aqueous solution of peanut proteins (PPE) with an oil phase including a polymer
Implementation Method 2
mixing the primary emulsion with a solution including one or more surfactants and/or stabilizers to form a secondary emulsion
Implementation Method 3
hardening the secondary emulsion by evaporation to remove the solvent
Implementation Method 4
freeze drying the nanoparticles
Data Source
AI summary
The present disclosure relates to a process for the preparation of tolerizing immune modifying nanoparticles encapsulating peanut proteins, compositions comprising the particles and use thereof for the treatment of peanut allergy.